
Please try another search
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which has completed Phase IV clinical trial; and Aminolevulinic acid–CIN, which has completed Phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid–AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid–acne, which is in phase II clinical trials for Acne; Aminolevulinic acid–gliomas for surgical visualization of gliomas; Aminolevulinic acid–bladder for surgical visualization of bladder cancer; and Aminolevulinic acid–breast for surgical visualization of breast cancer. In addition, it offers Osmotic pump technology platform drugs, which includes controlled-release carbidopa/levodopa Tablets which have complected phase II clinical trials for Early Parkinson’s disease; and Obeticholic acid for the treatment of hepatobiliary/autoimmune diseases. Further, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. Additionally, the company engages in the technology development, transfer, consulting, and promotion activities. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. was founded in 1996 and is based in Shanghai, the People's Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Yu Kuan Tang | 46 | 2020 | Chairman of Supervisory Committee |
Xiao Yang Yu | 67 | 2013 | Non-Executive Director |
Hong Guang Wang | - | 2023 | Independent Non-Executive Director |
Siu Wing Lam | - | 2023 | Independent Non-Executive Director |
Pei Long Xu | - | 2023 | Independent Non-Executive Director |
Bo Shen | 50 | 2012 | Non Executive Director |
Ai Guo Zhou | 55 | 2023 | Supervisor |
Jian Huang | 54 | 2017 | Independent Chairman of Supervisory Board |
Ya Nan Qu | 38 | 2023 | Employee Representative Supervisor |
Xue Yan | 43 | 2010 | CFO, Deputy GM, Company Secretary & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review